This longitudinal studyassessedfatigue and treatment status in patients with Atypical hemolytic uremic syndrome (aHUS) from the Global aHUS Registry.
The results confirm the detrimental effects of aHUS on patients’ daily lives, especially in terms of fatigue,butdemonstratessignificant improvement in symptoms following treatment with eculizumab.
Kidney International® Outcomes From the International Society of Nephrology Hemolytic Uraemic Syndromes... read more
Two significant research studies were accepted as late-breaking clinical trials at... read more
Kidney International® A Randomized, Open-label Clinical Trial Examined the Effects of Canagliflozin... read more
Kidney International® Patients With Crush Syndrome and Kidney Disease: Lessons Learned From... read more
Calling all early-career researchers! Have you published original research in Kidney International®... read more
Kidney International® Pre-transplant Anti-nephrin Antibodies are Specific Predictors of Recurrent Diffuse Podocytopathy... read more
Kidney International® NAVKIDS2: A Lesson in Matching Outcomes Measures to Interventions The... read more
Kidney International® Repurposing Drugs for Diseases Associated With Podocyte Dysfunction Podocyte disorders often... read more
Kidney International® Fluid Management Protocols in Hemodialysis Patients Using Bioimpedance Validation: Time... read more
Kidney International ® Managing the Symptom Burden Associated With Maintenance Dialysis: Conclusions... read more
